Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
Published in
Speakers
Dr. Lori Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan where she is currently Professor with tenure in Radiation Oncology. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds.
Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.
Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching awards from the University of Michigan and multiple national organizations. Honors include receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists’ Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Most recently, Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021. She is currently Chair of the Board.
Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.
Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching awards from the University of Michigan and multiple national organizations. Honors include receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists’ Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Most recently, Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021. She is currently Chair of the Board.
Published in
Speakers
Deborah Doroshow, MD, PhD is Assistant Professor of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. She divides her clinical practice and research between the Center for Thoracic Oncology, where she sees patients with lung cancer, and the Early Phase Trials Unit, where she sees patients with a variety of solid tumors on phase 1 and 2 trials of novel agents. Her research, for which she was awarded a 2021 ASCO Career Development Award, focuses on the use of targeted therapies to treat cancer and examines the use of novel agents to target DNA damage and repair processes.
Published in
Speakers
Vali Papadimitrakopoulou, M.D., Vice President, Clinical Development Leader, GPD Pfizer Oncology, is recognized around the world for her expertise in personalized genomics-driven cancer therapies, immunotherapies, translational research and cancer chemoprevention. She joined Pfizer In September 2019 from the University of Texas MD Anderson Cancer Center, where she was an Endowed Professor of Medicine and Section Chief of Thoracic Oncology in the Department of Thoracic/Head and Neck Medical Oncology. Vali oversees the whole Pfizer Oncology clinical development portfolio and a global team that spans hematology and solid tumors. She has led numerous clinical and translational research projects focused on the development of biomarker-based targeted therapies to overcome therapeutic resistance in advanced disease. Vali recently has been a member of the FDA’s Oncologic Drugs Advisory Committee (ODAC) and has served as co-principal investigator on the Master Lung Protocol (Lung-MAP) study, a pioneering umbrella trial simultaneously testing multiple precision medicines in squamous cell lung cancer, supported by the National Cancer Institute and run through a unique and groundbreaking partnership between patient advocacy organizations, pharmaceutical companies (including Pfizer) and public institutions. Vali has extensive experience leading the design and implementation of innovative clinical development programs in oncology, managing multidisciplinary research teams, and spearheading collaborative efforts within and across the global oncology community. Vali received her medical degree from the University of Patras School of Medicine, completed residencies at Institut Gustave Roussy in Paris and Columbia Presbyterian Medical Center in New York and fellowship at the MD Anderson Cancer Center and currently pursuing an Executive MBA at the Massachusetts Institute of Technology Sloan School of Management. She is the recipient of numerous awards and honors including, most recently, the 2018 Addario Lectureship Award from the Bonnie J. Addario Lung Cancer Foundation and MD Anderson Cancer Center’s 2017 Irwin H. Krakoff Award of Excellence in Clinical Research. She is the lead author or co-author of more than 200 publications, including articles in the New England Journal of Medicine, Nature and the Journal of Clinical Oncology.
Published in
Speakers
David H. Harpole, Jr. is a Professor of Surgery in the Division of Thoracic Surgery at the Duke University Medical Center in Durham, North Carolina, where he serves as Director of the Duke Surgical Research Fellowship and leads Duke’s Lung Cancer Research Laboratory and Biorepository. Dr. Harpole received his medical degree from the University of Virginia in Charlottesville, Virginia in 1984 and completed his General and Thoracic Surgery Residencies in 1993 under Dr. David Sabiston at Duke University where he also was the Posthelwaite Thoracic Research fellow from 1986-1988. After completion, he joined the faculty of the Division of Thoracic Surgery at the Brigham and Women’s under the leadership of Dr. David Sugarbaker from 1993-1996. He established a research laboratory under the mentorship of Dr. Judah Folkman at the Dana Farber Cancer Institute where he received his first NIH R-grant as a PI. He was recruited back to Duke to establish the General Thoracic Surgery program and the Thoracic Oncology Research Laboratory in 1996. He has risen to the rank of Full Professor of Surgery with tenure and is a Full Professor of Pathology at the Duke University Medical Center in Durham, North Carolina.
Dr. Harpole has served in the Department of Surgery and Division of Thoracic Surgery for the past 20+ years; as Vice-chairman for Faculty Affairs, Vice-chief of The Division of Surgical Sciences and Vice Chairman for Research. He also served as the Surgical coordinator for Duke University Medical Center, Cancer and Leukemia Group B, Chairman, Society of Thoracic Surgeons: General Thoracic Surgery Database Committee, Chairman of the Thoracic Surgery Sub-committee, CALGB and Vice-chairman, American College of Surgeons Oncology Group. He also was the Co-chair of the Thoracic Tumor Committee of the National Cancer Database and recently retired as a Director of the American Board of Thoracic Surgery and completed his role as a Board of Director of the International Association for the Study of Lung Cancer. He will be conference president of 2021 World Conference on Lung Cancer (WCLC).
Dr. Harpole has contributed numerous articles (> 200) and abstracts to the medical literature. His work on non-small cell lung cancer, esophageal carcinoma and mesothelioma. He has directed an active translational thoracic oncology research laboratory for more 25 years that has had National Institutes of Health, Veterans Affairs and Department of Defense peer reviewed grant support and has served on NCI and VA grant review study sections for more than 15 years, including chair of the NCI R03, R21, R33 grant review study section for the last 4 years. He has led several large multi-institutional lung cancer clinical trials based on his laboratory efforts. Over the last 8 years, he was the co-chair of the NCI-CTEP Thoracic Malignancies Steering Committee that oversees all large clinical trials in lung cancer and mesothelioma in the US and Canada.
Dr. Harpole is an internationally-recognized expert in thoracic oncology in translational science, clinical research and education. He is also one of the innovators of minimally-invasive approaches to lung cancer and the multi-modality treatment of mesothelioma. Over the last two+ decades, he has trained and mentored more than 20 research fellows who hold academic positions across the US and Canada. Currently, he is the PI of three NIH-funded training grants (NCI T32, NHLBI R38 and NIAID R38).
Dr. Harpole has served in the Department of Surgery and Division of Thoracic Surgery for the past 20+ years; as Vice-chairman for Faculty Affairs, Vice-chief of The Division of Surgical Sciences and Vice Chairman for Research. He also served as the Surgical coordinator for Duke University Medical Center, Cancer and Leukemia Group B, Chairman, Society of Thoracic Surgeons: General Thoracic Surgery Database Committee, Chairman of the Thoracic Surgery Sub-committee, CALGB and Vice-chairman, American College of Surgeons Oncology Group. He also was the Co-chair of the Thoracic Tumor Committee of the National Cancer Database and recently retired as a Director of the American Board of Thoracic Surgery and completed his role as a Board of Director of the International Association for the Study of Lung Cancer. He will be conference president of 2021 World Conference on Lung Cancer (WCLC).
Dr. Harpole has contributed numerous articles (> 200) and abstracts to the medical literature. His work on non-small cell lung cancer, esophageal carcinoma and mesothelioma. He has directed an active translational thoracic oncology research laboratory for more 25 years that has had National Institutes of Health, Veterans Affairs and Department of Defense peer reviewed grant support and has served on NCI and VA grant review study sections for more than 15 years, including chair of the NCI R03, R21, R33 grant review study section for the last 4 years. He has led several large multi-institutional lung cancer clinical trials based on his laboratory efforts. Over the last 8 years, he was the co-chair of the NCI-CTEP Thoracic Malignancies Steering Committee that oversees all large clinical trials in lung cancer and mesothelioma in the US and Canada.
Dr. Harpole is an internationally-recognized expert in thoracic oncology in translational science, clinical research and education. He is also one of the innovators of minimally-invasive approaches to lung cancer and the multi-modality treatment of mesothelioma. Over the last two+ decades, he has trained and mentored more than 20 research fellows who hold academic positions across the US and Canada. Currently, he is the PI of three NIH-funded training grants (NCI T32, NHLBI R38 and NIAID R38).
Published in
Speakers
I am cardiothoracic surgeon and I was Chief Investigator of the MARS trial and the PulMiCC trial
A summary of my roles can be found on the web at
https://www.ctsnet.org/home/ttreasure
A summary of my roles can be found on the web at
https://www.ctsnet.org/home/ttreasure
Published in
Speakers
Lucía Carolina Viola is an institutional member of the Fundación Neumológica Colombiana in Bogotá, Colombia, South America. She obtained his medical degree at the Universidad del Sinú (Cartagena, Colombia) and then she did postgraduate studies in internal medicine (Universidad de la Sabana, Chía, Colombia), and pulmonology (Universidad de la Sabana, Chía, Colombia).
Her current areas of interest and emphasis include the search for biomarkers to early diagnosis of lung cancer, early detection programs based on traditional strategies as low dose computed tomography, early detection programs in low income countries and in never smokers. She is the leader of the early detection program of her institution.
Her current areas of interest and emphasis include the search for biomarkers to early diagnosis of lung cancer, early detection programs based on traditional strategies as low dose computed tomography, early detection programs in low income countries and in never smokers. She is the leader of the early detection program of her institution.
Published in
Speakers
Medical Oncologist NOB Oncoclinicas; President Brazilian Society of Clinical Oncology; Board Member IASLC and Past Chair IAC
Published in
Speakers
Published in
Speakers
Published in
Speakers
